Baseline clinical characteristics and CMR findings
| N=81 | |||
|---|---|---|---|
| Age, years | 62.9±13.0 | Device implantation | |
| Female | 49 (60.5) | Pacemaker | 11 (13.6) |
| ACE, IU/L | 18.1±10.0 | ICD/CRT-D | 8 (9.9) |
| BNP, pg/mL | 151.3±172.3 | CMR parameters | |
| Involvement | LV EDV, mL | 157.7±61.7 | |
| Lung | 20 (24.7) | LV ESV, mL | 91.2±58.7 |
| Skin | 12 (14.8) | LV EF, % | 45.9±14.6 |
| Eye | 17 (21.0) | LV mass index, g/m2 | 68.2±19.1 |
| Other | 6 (7.4) | T2 positive | 47 (58.8) |
| JMHW criteria, positive | 35 (43.2) | % LGE area,% | 16.6±12.9 |
| Medication | Fibrosis mass index, g/m2 | 11.3±9.6 | |
| ACEi or ARB | 29 (35.8) | LV morphological abnormality | |
| β-blocker | 25 (30.9) | Thinning | 21 (25.9) |
| Diuretic | 26 (32.1) | Aneurysmal | 13 (16.0) |
| Corticosteroid | 15 (18.5) | ||
| Antiarrhythmic drug | 15 (18.5) | ||
| Cardiac symptoms | |||
| NYHA functional class ≥II | 24 (29.6) | ||
| Admission due to HF | 16 (19.8) | ||
| Syncope | 22 (29.7) | ||
| Atrial fibrillation | 10 (12.3) | ||
| Advanced AV block | 20 (24.7) | ||
| VA | 31 (42.5) |
Values are the mean±SD or number (%).
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; AV, atrioventricular; BNP, B-type natriuretic peptide; CRT-D, cardiac resynchronisation therapy-defibrillator; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; HF, heart failure; HT, hypertension; ICD, implantable cardioverter defibrillator; JMHW, Japanese Ministry of Health and Welfare; LGE, late gadolinium enhancement; LV, left ventricular; NYHA, New York Heart Association; VA, ventricular tachyarrhythmia.